LIN SUE-JEAN
SEC Form 4 insider trading activity
LIN SUE-JEAN has filed 4 SEC Form 4 filings (6 transaction rows) across 2 companies, including STVN, ARQT, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jun 26, 2026.
On the most recent filing, LIN SUE-JEAN is listed as Director at Arcutis Biotherapeutics, Inc. Inside the rolling window, LIN SUE-JEAN reported no open-market purchases and 2 open-market sales totaling $899K in ARQT. The largest disclosed transaction in the window is a sale of 25,272 ARQT shares on Nov 24, 2025, worth $778K.
Companies traded
Other insiders at STVN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$899K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has LIN SUE-JEAN made?
LIN SUE-JEAN has filed 4 SEC Form 4 filings (6 transaction rows) across 2 companies, including STVN, ARQT since 2025.
Which companies does LIN SUE-JEAN trade?
LIN SUE-JEAN has filed SEC Form 4 disclosures for 2 companies, including STVN, ARQT.
When was LIN SUE-JEAN's most recent SEC Form 4 filing?
LIN SUE-JEAN's most recent SEC Form 4 filing on Tracefour is dated Jun 26, 2026.
What is LIN SUE-JEAN's total buy and sell value in the current window?
Inside the rolling retention window, LIN SUE-JEAN bought $0 and sold $899K based on SEC Form 4 filings.
What was LIN SUE-JEAN's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 25,272 ARQT shares on 2025-11-24, worth $778K, per SEC Form 4 filings.